Clinical Trials · NCT03511768
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
- Phase
- Phase 1/Phase 2
- Recruitment status
- Unknown
- Sponsor
- Xiangya Hospital of Central South University
- Enrollment
- 65
- Start date
- Jan 2018
- Locations
- 1 site, China
- Primary endpoint
- 18F-AlF-NOTA-octreotide PET/CT imaging of patients with Neuroendocrine Neoplasms